Literature DB >> 31734779

Prognostic and predictive value of nuclear imaging in endocrine oncology.

Giorgio Treglia1,2,3,4, Bernard Goichot5, Luca Giovanella1,6, Elif Hindié7,8, Abhishek Jha9, Karel Pacak9, David Taïeb10,11, Thomas Walter12,13, Alessio Imperiale14,15.   

Abstract

In the last few years, the role and use of medical technologies in (neuro)endocrine oncology has greatly evolved allowing not only important diagnostic information but also prognostic stratification in different clinical situations. The terms "prognostic" and "predictive" are commonly used to describe the relationships between biomarkers and patients' clinical outcomes but have quite different meaning. The present work discusses the prognostic and predictive value of nuclear medicine imaging. It critically reviews the clinical significance and potential impact of molecular examinations on follow-up and therapeutic strategies in patients with neuroendocrine neoplasms, thyroid tumors, and adrenal malignancies.

Entities:  

Keywords:  Endocrinology; Neuroendocrine; Nuclear medicine; PET; Predictive; Prognostic

Mesh：

Year:  2019        PMID： 31734779      PMCID： PMC7441826          DOI： 10.1007/s12020-019-02131-4

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


  74 in total

1.  Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib.

Authors:  Gary M Clark
Journal:  Mol Oncol       Date:  2007-12-08       Impact factor: 6.603

2.  Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.

Authors:  Tessa Brabander; Wouter A van der Zwan; Jaap J M Teunissen; Boen L R Kam; Richard A Feelders; Wouter W de Herder; Casper H J van Eijck; Gaston J H Franssen; Eric P Krenning; Dik J Kwekkeboom
Journal:  Clin Cancer Res       Date:  2017-04-20       Impact factor: 12.531

Review 3.  Role of positron emission tomography in thyroid and neuroendocrine tumors.

Authors:  Giorgio Treglia; Alexander S Kroiss; Arnoldo Piccardo; Filippo Lococo; Prasanna Santhanam; Alessio Imperiale
Journal:  Minerva Endocrinol       Date:  2017-09-25       Impact factor: 2.184

4.  SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework.

Authors:  Rudolf A Werner; Lilja B Solnes; Mehrbod S Javadi; Alexander Weich; Michael A Gorin; Kenneth J Pienta; Takahiro Higuchi; Andreas K Buck; Martin G Pomper; Steven P Rowe; Constantin Lapa
Journal:  J Nucl Med       Date:  2018-03-23       Impact factor: 10.057

5.  Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.

Authors:  Arthi Vijayaraghavan; Molly B Efrusy; Burkhard Göke; Thomas Kirchner; Christopher C Santas; Richard M Goldberg
Journal:  Int J Cancer       Date:  2012-01-03       Impact factor: 7.396

6.  Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients.

Authors:  Camilla B Johnbeck; Ulrich Knigge; Seppo W Langer; Annika Loft; Anne Kiil Berthelsen; Birgitte Federspiel; Tina Binderup; Andreas Kjaer
Journal:  J Nucl Med       Date:  2016-07-28       Impact factor: 10.057

7.  (18)F-FDG uptake at initial staging of the adrenocortical cancers: a diagnostic tool but not of prognostic value.

Authors:  L Tessonnier; C Ansquer; C Bournaud; F Sebag; E Mirallié; J C Lifante; F F Palazzo; I Morange; D Drui; C de la Foucardère; J Mancini; D Taïeb
Journal:  World J Surg       Date:  2013-01       Impact factor: 3.352

8.  Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.

Authors:  Samer Ezziddin; Linda Adler; Amir Sabet; Thorsten Dirk Pöppel; Florian Grabellus; Ali Yüce; Hans-Peter Fischer; Birgit Simon; Tobias Höller; Hans-Jürgen Biersack; James Nagarajah
Journal:  J Nucl Med       Date:  2014-05-29       Impact factor: 10.057

9.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.

Authors:  Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

Review 10.  Prognosis Research Strategy (PROGRESS) 2: prognostic factor research.

Authors:  Richard D Riley; Jill A Hayden; Ewout W Steyerberg; Karel G M Moons; Keith Abrams; Panayiotis A Kyzas; Núria Malats; Andrew Briggs; Sara Schroter; Douglas G Altman; Harry Hemingway
Journal:  PLoS Med       Date:  2013-02-05       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.